Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ticagrelor
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Indoco launches Ticagrelor film-coated tablets 90mg in the UK market
Details : Ticagrelor tablets are indicated to reduce the risk of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome.
Product Name : Ticagrelor-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 03, 2025
Lead Product(s) : Ticagrelor
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ticagrelor
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alembic Receives USFDA Final Approval for Ticagrelor Tablets
Details : Ticagrelor tablets are indicated to reduce the risk of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome.
Product Name : Brilinta-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 03, 2025
Lead Product(s) : Ticagrelor
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ticagrelor
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Morepen Laboratories Expands Its Domestic Portfolio
Details : Ticapen (ticagrelor) mechanism of action involves inhibiting platelet activation and aggregation by reversibly binding to the P2Y12 receptor, to reduce the risk of stroke and heart attack.
Product Name : Ticapen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 25, 2025
Lead Product(s) : Ticagrelor
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ticagrelor
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : PharmEvo
Deal Size : Inapplicable
Deal Type : Inapplicable
TADCLOT- a Double Blind Randomized Controlled Trial
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2024
Lead Product(s) : Ticagrelor
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : PharmEvo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ticagrelor
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2024
Lead Product(s) : Ticagrelor
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ticagrelor
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2021
Lead Product(s) : Ticagrelor
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ticagrelor
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : National Institute of Neurological Disorders and Stroke | University of Cincinnati | Medical University of South Carolina | Johnson & Johnson Innovative Medicine | AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2021
Lead Product(s) : Ticagrelor
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : National Institute of Neurological Disorders and Stroke | University of Cincinnati | Medical University of South Carolina | Johnson & Johnson Innovative Medicine | AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ticagrelor
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 15, 2021
Lead Product(s) : Ticagrelor
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ticagrelor
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : PharmEvo Private Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2021
Lead Product(s) : Ticagrelor
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : PharmEvo Private Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ticagrelor
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Advice Pharma Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2021
Lead Product(s) : Ticagrelor
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Advice Pharma Group
Deal Size : Inapplicable
Deal Type : Inapplicable